TP53 and neoplasm: Indeed, previous reports have shown a greater effectiveness of antiangiogenic scheduling of chemotherapy in p53‐null mice (Browder et al, 2000) and that repression of p53 in tumor stroma sensitizes p53‐deficient tumors to radiotherapy and cyclophosphamide chemotherapy (Burdelya et al, 2006).